Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of autologous tumor RNA-loaded dendritic cell vaccine manufacturing in adults with esophageal adenocarcinoma or pancreatic cancer
NL-OMON32620Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2010
- Countries
- 1
01
Overview
Open-label trial in esophageal adenocarcinoma (EAC) and pancreatic cancer (PC) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Vaccine release criteria, Functional dendritic cell yield and 1 more. Planned start Jan 2010; status: not yet recruiting.
02
Conditions
esophageal adenocarcinoma (EAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON32620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32620.